Actively Recruiting
Phase 2 Clinical Trial Evaluating PD-L1-Targeted Radionuclide Probes for Imaging Solid Tumors
Led by Peking University Cancer Hospital & Institute · Updated on 2026-09-29
50
Participants Needed
1
Research Sites
21 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the use of a molecular imaging probe called 18FF-PDL1-3 to detect PD-L1 expression in primary and metastatic tumors in patients with various solid tumors, including lung, cervical, melanoma, breast, and gastrointestinal cancers. This Phase 2 study aims to assess the heterogeneity of PD-L1 expression within and between lesions, monitor changes over time, and explore how this imaging method may support targeted treatment decisions. Participants will receive intravenous injections of 18FF-PDL1-3 followed by whole-body PETCT imaging at 1, 2, and 3 hours post-injection using specialized scanners. Some participants will also undergo dynamic scanning for 40 minutes immediately after injection. The study includes comparison of PD-L1 imaging results with traditional tissue biopsy findings. Additionally, participants receive an injection of 18F-FDG with subsequent PETCT imaging for comprehensive evaluation. During the study, participants complete multiple imaging sessions, and researchers collect medical records, lab results, pathology, and other imaging data for up to three months after imaging. Safety is monitored for tracer-related adverse events up to seven days after injection. The main outcomes include imaging feasibility, radiochemical purity, and standardized uptake values. This process helps understand the tracers behavior and supports personalized tumor treatment strategies.
CONDITIONS
Brief Title
Clinical Investigator-Initiated Trial (IIT) of PD-L1-Targeted Radionuclide Probes
Research Team
H
Hua Zhu
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here